I agree that this site is using cookies. You can find further informations here.
X
Dahle, Jostein
94  results:
Search for persons X
?
1

Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes w..:

Malenge, Marion M. ; Maaland, Astri Fjelde ; Repetto-Llamazares, Ada...
PLOS ONE.  17 (2022)  4 - p. e0267543 , 2022
Link: https://doi.org/10.1371/..
 
?
2

89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 an..:

Giesen, Danique ; Hooge, Marjolijn N. Lub-de ; Nijland, Marcel...
Scientific Reports.  12 (2022)  1 - p. , 2022
Link: https://doi.org/10.1038/..
 
?
3

FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetr..:

Løndalen, Ayca ; Blakkisrud, Johan ; Revheim, Mona-Elisabeth...
Molecular Imaging and Biology.  24 (2022)  5 - p. 807-817 , 2022
Link: https://doi.org/10.1007/..
 
?
4

Myelosuppression in patients treated with177Lutetium-liloto..:

Blakkisrud, Johan ; Løndalen, Ayca ; Dahle, Jostein...
Acta Oncologica.  60 (2021)  11 - p. 1481-1488 , 2021
Link: https://doi.org/10.1080/..
 
?
5

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapse..:

Kolstad, Arne ; Illidge, Tim ; Bolstad, Nils...
Blood Advances.  4 (2020)  17 - p. 4091-4101 , 2020
Link: https://doi.org/10.1182/..
 
?
6

FDG PET/CT parameters and correlations with tumor-absorbed ..:

Løndalen, Ayca ; Blakkisrud, Johan ; Revheim, Mona-Elisabeth...
European Journal of Nuclear Medicine and Molecular Imaging.  48 (2020)  6 - p. 1902-1914 , 2020
Link: https://doi.org/10.1007/..
 
?
7

Targeted alpha therapy for chronic lymphocytic leukaemia an..:

Maaland, Astri Fjelde ; Saidi, Amal ; Torgue, Julien...
PLOS ONE.  15 (2020)  3 - p. e0230526 , 2020
Link: https://doi.org/10.1371/..
 
?
8

Targeting B-cell malignancies with the beta-emitting anti-C..:

Maaland, Astri Fjelde ; Heyerdahl, Helen ; O'Shea, Adam...
European Journal of Nuclear Medicine and Molecular Imaging.  46 (2019)  11 - p. 2311-2321 , 2019
Link: https://doi.org/10.1007/..
 
?
9

The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses R..:

Rødland, Gro Elise ; Melhus, Katrine ; Generalov, Roman...
Frontiers in Oncology.  9 (2019)  - p. , 2019
Link: https://doi.org/10.3389/..
 
?
10

The therapeutic effectiveness of 177Lu-lilotomab in B-cell ..:

Pichard, Alexandre ; Marcatili, Sara ; Karam, Jihad...
Leukemia.  34 (2019)  5 - p. 1315-1328 , 2019
Link: https://doi.org/10.1038/..
 
?
11

Pre-dosing with lilotomab prior to therapy with 177Lu-lilot..:

Stokke, Caroline ; Blakkisrud, Johan ; Løndalen, Ayca...
European Journal of Nuclear Medicine and Molecular Imaging.  45 (2018)  7 - p. 1233-1241 , 2018
Link: https://doi.org/10.1007/..
 
?
12

Administration of Beta-Emitting Anti-CD37 Radioimmunoconjug..:

Heyerdahl, Helen ; Repetto-Llamazares, Ada H.V. ; Dahle, Jostein
Journal of Cancer Biology and Therapeutics.  4 (2018)  1 - p. 181-190 , 2018
Link: https://doi.org/10.18314..
 
?
13

[OA170] Myelosuppression in non–hodgkin lymphoma patients t..:

Blakkisrud, Johan ; Løndalen, Ayca ; Dahle, Jostein...
Physica Medica.  52 (2018)  - p. 65 , 2018
Link: https://doi.org/10.1016/..
 
?
14

Combination of 177Lu‐lilotomab with rituximab significantly..:

Repetto‐Llamazares, Ada H. V. ; Malenge, Marion M. ; O'Shea, Adam...
European Journal of Haematology.  101 (2018)  4 - p. 522-531 , 2018
Link: https://doi.org/10.1111/..
 
?
15

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particl..:

Repetto-Llamazares, Ada H. V. ; Larsen, Roy H. ; Patzke, Sebastian...
PLOS ONE.  10 (2015)  6 - p. e0128816 , 2015
Link: https://doi.org/10.1371/..
 
1-15